Diabetes CarediacaredcareDiabetes CareDiabetes Care0149-59921935-5548American Diabetes Association215052053114364002010.2337/dc11-0020Original ResearchEpidemiology/Health Services ResearchAssociation Between Diagnosed Diabetes and Self-Reported Cancer Among U.S. AdultsFindings from the 2009 Behavioral Risk Factor Surveillance SystemLiChaoyangMDPHD1BalluzLina S.MPHSCD1FordEarl S.MDMPH2OkoroCatherine A.MS1TsaiJamesMDMPH3ZhaoGuixiangMDPHD21Division of Behavioral Surveillance, Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia2Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia3Division of Blood Disorders, National Center for Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GeorgiaCorresponding author: Chaoyang Li, cli@cdc.gov.620112052011346136513684120111332011© 2011 by the American Diabetes Association.2011Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.OBJECTIVE

To assess the association between diagnosed diabetes and self-reported cancer among U.S. adults.

RESEARCH DESIGN AND METHODS

We analyzed data for 397,783 adults who participated in the 2009 Behavioral Risk Factor Surveillance System and had valid data on diabetes and cancer.

RESULTS

After adjustment for potential confounders, diabetic men had higher adjusted prevalence ratios for cancers of the prostate (1.1 [95% CI 1.0–1.3]), colon (1.3 [1.0–1.7]), pancreas (4.6 [1.8–11.7]), rectum (2.2 [1.0–4.7]), urinary bladder (1.7 [1.2–2.2]), and kidney (1.9 [1.2–3.0]) than nondiabetic men (all P < 0.05). Diabetic women had higher adjusted prevalence ratios for cancers of the breast (1.1 [1.0–1.3]) and endometrium (1.6 [1.2–2.0]), and leukemia (2.3 [1.3–4.2]) than nondiabetic women (all P < 0.05).

CONCLUSIONS

Our results suggest that diabetic adults have higher prevalences of certain cancers than nondiabetic adults.

Diabetes and cancer are two common chronic diseases that exert serious adverse effects on public health in the U.S. Approximately 25.6 million adults (11.3%) aged 20 years or older were estimated to have diabetes in 2010 (1). Approximately 11.7 million Americans were living with cancer in 2007. Studies have found that diabetes is associated with an increased risk for certain types of cancer (2,3), and diabetes may increase the risk of all-cause mortality among people with cancer (4). To compare the prevalence of cancer between adults without and with diabetes, we analyzed a large population–based sample from the Centers for Disease Control and Prevention 2009 Behavioral Risk Factor Surveillance System (BRFSS) in the U.S.

RESEARCH DESIGN AND METHODS

The BRFSS is a standardized telephone survey that annually assesses key behavioral risk factors and chronic diseases among adults aged 18 years or older in all U.S. states, District of Columbia, and territories. The median cooperation rate among states was 75.0% in 2009 (5). BRFSS data have consistently provided valid and reliable estimates compared with national household surveys (6,7).

Diabetes status was ascertained by asking participants, “Have you ever been told by a doctor that you have diabetes?” Responses were coded as “yes,” “yes, but female told only during pregnancy,” or “no.” Gestational diabetes was coded as “no” diabetes.

Cancer status was ascertained by asking participants, “Have you ever been told by a doctor, nurse, or other health professional that you have cancer?” Responses were coded as “yes,” or “no.” For those who answered “yes” to this question, the following questions were asked, “With your most recent diagnoses of cancer, what type of cancer was it?” The survey included 10 major cancer sites/tracts and 29 cancer types: breast cancer, male reproductive tract (prostate cancer, testicular cancer), head/neck (head and neck cancer, oral cancer, pharyngeal cancer, thyroid cancer), gastrointestinal tract (colon cancer, esophageal cancer, liver cancer, pancreatic cancer, rectal cancer, stomach cancer), leukemia/lymphoma (Hodgkin’s lymphoma, leukemia, non–Hodgkin’s lymphoma), skin (melanoma, other skin cancer), lung cancer, urinary tract (urinary bladder cancer, kidney cancer), and other sites (heart cancer, bone cancer, brain cancer, neuroblastoma, other).

Demographic characteristics included sex, age (year), and race/ethnicity (non–Hispanic white, non–Hispanic black, Hispanic, and other). Health-related risk factors included health insurance coverage (none vs. any type of health insurance), smoking status (current smoker, former smoker, and never smoked), heavy drinking (consuming more than two drinks per day among men and more than one drink per day among women), BMI (kg/m2), and physical inactivity.

We estimated the crude prevalence for cancer of all sites and specific types of cancer according to diabetes status. We estimated the prevalence ratios and their 95% CIs using log-linear models with a robust error variance estimator (8). The equality in the prevalence estimates was tested with a two-sample t test. We considered results with a two-tailed P value <0.05 or the 95% CI of a prevalence ratio estimate that did not include 1 to be statistically significant.

We conducted all analyses using SUDAAN 9.0 software (Research Triangle Institute, Research Triangle Park, NC) to account for the complex sampling design.

RESULTS

The final analytic sample of 397,783 individuals (mean age, 46.8 years; range, 18–99 years or older; SE = 0.06 years) consisted of 151,459 men (38.1%), 318,070 non–Hispanic whites (80.0%), 31,168 non–Hispanic blacks (7.8%), 26,764 Hispanics (6.7%), and 21,781 other racial/ethnic participants (5.5%).

After adjustment for age and all other potential confounders, men with diabetes had significantly higher prevalences of cancer of all sites and cancers of the prostate, colon, pancreas, rectum, urinary bladder, and kidney than men without diabetes (Table 1). Women with diabetes had significantly higher prevalences of cancer of all sites and cancers of the breast and endometrium as well as leukemia than women without diabetes (all P < 0.05). Diabetic men had a higher prevalence of liver cancer, whereas diabetic women had a higher prevalence of liver cancer and pancreatic cancer than their nondiabetic counterparts, albeit no statistical significance was detected (P = 0.07–0.13).

Prevalences and prevalence ratios of cancer according to diabetes status among men and women, BRFSS 2009

Cancer site/tractCancer typeCrude prevalence, % (SE)
Prevalence ratio (95% CI)
DiabetesNo diabetesPModel 1*Model 2Model 3
Men, N19,719131,740
All cancers15.89 (0.45)7.49 (0.11)<0.00012.1 (2.0–2.3)1.1 (1.0–1.1)1.1 (1.1–1.2)
 Breast cancer0.10 (0.04)0.02 (0.01)0.0295.2 (2.1–12.7)3.0 (1.2–7.1)1.5 (0.4–4.8)
 Male reproductive5.35 (0.31)2.06 (0.06)<0.00012.6 (2.3–3.0)1.1 (1.0–1.3)1.1 (1.0–1.3)
Prostate5.11 (0.31)1.89 (0.05)<0.00012.7 (2.4–3.1)1.2 (1.0–1.3)1.1 (1.0–1.3)
Testicular0.27 (0.06)0.18 (0.03)0.201.5 (0.9–2.5)1.2 (0.7–2.1)1.1 (0.5–2.2)
 Head/neck0.58 (0.09)0.27 (0.02)0.00062.2 (1.6–3.1)1.2 (0.8–1.6)1.2 (0.8–1.7)
Head and neck0.11 (0.04)0.06 (0.01)0.181.9 (0.9–3.8)1.0 (0.5–2.0)1.2 (0.6–2.5)
Oral0.07 (0.03)0.05 (0.01)0.431.5 (0.6–3.4)0.9 (0.4–1.8)0.9 (0.4–2.1)
Pharyngeal0.14 (0.04)0.06 (0.01)0.0662.2 (1.2–4.2)1.0 (0.5–1.9)1.0 (0.5–1.9)
Thyroid0.26 (0.07)0.10 (0.01)0.0142.7 (1.5–4.8)1.6 (0.9–2.8)1.4 (0.8–2.6)
 Gastrointestinal1.90 (0.17)0.58 (0.03)<0.00013.2 (2.7–4.0)1.5 (1.2–1.8)1.4 (1.2–1.8)
Colon1.37 (0.15)0.42 (0.02)<0.00013.2 (2.5–4.1)1.5 (1.1–1.8)1.3 (1.0–1.7)
Esophageal0.03 (0.01)0.03 (0.01)0.951.0 (0.5–2.1)0.4 (0.2–0.9)0.6 (0.3–1.4)
Liver0.12 (0.04)0.03 (0.01)0.0223.7 (1.8–7.6)1.9 (0.9–4.0)1.8 (0.9–3.4)
Pancreatic0.16 (0.07)0.02 (0.01)0.0347.0 (2.8–17.3)3.4 (1.4–8.3)4.6 (1.8–11.7)
Rectal0.14 (0.04)0.03 (0.01)0.0034.7 (2.6–8.8)2.1 (1.1–4.0)2.2 (1.0–4.7)
Stomach0.09 (0.03)0.04 (0.01)0.122.2 (1.0–4.5)1.1 (0.5–2.2)1.0 (0.4–2.5)
 Leukemia/lymphoma0.68 (0.10)0.44 (0.04)0.0261.6 (1.1–2.2)1.0 (0.7–1.4)1.1 (0.8–1.6)
Hodgkin’s lymphoma0.32 (0.08)0.14 (0.02)0.0232.4 (1.4–4.1)1.7 (0.9–3.0)1.8 (0.9–3.4)
Leukemia0.15 (0.04)0.13 (0.02)0.611.2 (0.7–2.1)0.7 (0.4–1.2)0.8 (0.5–1.6)
Non–Hodgkin’s lymphoma0.21 (0.05)0.17 (0.03)0.531.2 (0.7–2.2)0.8 (0.5–1.4)0.8 (0.4–1.4)
 Skin5.57 (0.27)3.09 (0.06)<0.00011.8 (1.6–2.0)0.9 (0.8–1.0)1.0 (0.9–1.1)
Melanoma2.01 (0.15)0.99 (0.04)<0.00012.0 (1.7–2.4)1.0 (0.8–1.2)1.1 (0.9–1.3)
Other skin3.71 (0.23)2.14 (0.05)<0.00011.7 (1.5–2.0)0.9 (0.8–1.0)1.0 (0.9–1.1)
 Lung0.38 (0.06)0.19 (0.02)0.00362.0 (1.3–2.9)0.9 (0.6–1.3)0.8 (0.5–1.4)
 Urinary1.35 (0.14)0.33 (0.02)<0.00014.1 (3.2–5.1)1.8 (1.4–2.3)1.7 (1.3–2.2)
Bladder0.86 (0.11)0.22 (0.02)<0.00014.0 (3.0–5.3)1.7 (1.3–2.3)1.7 (1.2–2.2)
Kidney0.50 (0.09)0.12 (0.01)<0.00014.3 (2.9–6.4)2.2 (1.4–3.3)1.9 (1.2–3.0)
 Other sites1.53 (0.15)0.70 (0.04)<0.00012.2 (1.8–2.7)1.2 (1.0–1.5)1.2 (1.0–1.6)
HeartRare§Rare
Bone0.11 (0.04)0.06 (0.02)0.281.9 (0.7–4.9)1.6 (0.7–3.9)1.5 (0.6–3.7)
Brain0.07 (0.03)0.04 (0.01)0.331.7 (0.7–3.9)1.6 (0.7–4.0)2.2 (0.9–5.6)
NeuroblastomaRareRare
Other1.36 (0.14)0.60 (0.03)<0.00012.3 (1.8–2.8)1.2 (0.9–1.5)1.2 (1.0–1.5)
Women, N28,699217,625
All cancers17.08 (0.39)10.37 (0.11)<0.00011.7 (1.6–1.7)1.1 (1.0–1.1)1.1 (1.1–1.2)
 Breast5.52 (0.24)2.87 (0.06)<0.00011.9 (1.8–2.1)1.1 (1.0–1.2)1.1 (1.0–1.3)
 Reproductive4.08 (0.25)2.22 (0.06)<0.00011.8 (1.6–2.1)1.5 (1.3–1.7)1.3 (1.2–1.6)
Cervical1.87 (0.15)1.36 (0.05)0.00111.4 (1.2–1.6)1.3 (1.1–1.6)1.2 (1.0–1.5)
Endometrial1.45 (0.17)0.45 (0.02)<0.00013.2 (2.5–4.1)2.0 (1.6–2.6)1.6 (1.2–2.0)
Ovarian0.87 (0.13)0.44 (0.03)0.00112.0 (1.4–2.7)1.5 (1.1–2.1)1.4 (0.9–2.0)
 Head/neck0.67 (0.08)0.42 (0.02)0.00231.6 (1.2–2.1)1.1 (0.8–1.4)1.1 (0.8–1.5)
Head and neck0.07 (0.02)0.05 (0.01)0.381.4 (0.7–2.9)0.8 (0.4–1.7)1.1 (0.5–2.2)
Oral0.07 (0.03)0.03 (0.01)0.212.0 (0.8–4.7)1.1 (0.4–2.6)1.0 (0.3–3.0)
Pharyngeal0.06 (0.02)0.03 (0.005)0.182.2 (0.9–5.0)1.3 (0.5–3.1)1.3 (0.6–3.0)
Thyroid0.48 (0.07)0.31 (0.02)0.0191.5 (1.1–2.1)1.1 (0.8–1.5)1.1 (0.8–1.6)
 Gastrointestinal1.42 (0.12)0.59 (0.03)<0.00012.4 (2.0–2.9)1.3 (1.1–1.5)1.2 (0.9–1.5)
Colon1.12 (0.10)0.47 (0.02)<0.00012.4 (2.0–2.9)1.3 (1.0–1.6)1.1 (0.9–1.4)
EsophagealRare0.02 (0.003)
Liver0.10 (0.04)0.02 (0.01)0.0714.7 (1.7–12.7)3.2 (1.1–9.3)2.9 (0.9–9.6)
Pancreatic0.08 (0.03)0.02 (0.005)0.0323.6 (1.6–7.8)2.0 (0.9–4.4)2.5 (0.9–6.8)
Rectal0.08 (0.03)0.04 (0.01)0.112.2 (1.1–4.7)1.2 (0.6–2.4)1.2 (0.5–2.8)
Stomach0.04 (0.01)0.03 (0.01)0.401.4 (0.7–3.0)0.8 (0.4–1.7)0.9 (0.4–2.0)
 Leukemia/lymphoma0.63 (0.09)0.36 (0.02)0.00191.8 (1.3–2.4)1.1 (0.9–1.5)1.2 (0.8–1.6)
Hodgkin’s lymphoma0.17 (0.05)0.12 (0.01)0.341.4 (0.8–2.5)1.0 (0.5–1.8)1.0 (0.5–1.8)
Leukemia0.30 (0.06)0.10 (0.01)0.00153.1 (1.9–4.9)2.0 (1.3–3.4)2.3 (1.3–4.2)
Non–Hodgkin’s lymphoma0.16 (0.03)0.14 (0.01)0.511.2 (0.8–1.8)0.7 (0.5–1.1)0.7 (0.4–1.1)
 Skin4.35 (0.20)3.25 (0.06)<0.00011.3 (1.2–1.5)0.8 (0.7–0.9)1.0 (0.9–1.2)
Melanoma1.35 (0.12)0.90 (0.03)0.00041.5 (1.2–1.8)0.9 (0.8–1.1)1.2 (1.0–1.5)
Other skin3.08 (0.16)2.39 (0.05)0.00011.3 (1.2–1.4)0.7 (0.7–0.8)1.0 (0.9–1.1)
 Lung0.37 (0.05)0.24 (0.02)0.03141.5 (1.1–2.2)0.8 (0.6–1.2)0.7 (0.4–1.1)
 Urinary0.43 (0.06)0.19 (0.01)0.00022.3 (1.7–3.2)1.2 (0.9–1.7)1.2 (0.8–1.6)
Bladder0.19 (0.04)0.10 (0.01)0.0092.0 (1.3–3.0)1.0 (0.7–1.5)0.9 (0.6–1.3)
Kidney0.24 (0.05)0.09 (0.01)0.00712.6 (1.6–4.4)1.6 (1.0–2.6)1.6 (0.9–2.7)
 Other sites1.60 (0.15)0.84 (0.04)<0.00011.9 (1.6–2.3)1.3 (1.0–1.5)1.2 (0.9–1.4)
HeartRareRare
Bone0.05 (0.02)0.05 (0.01)0.941.0 (0.5–2.1)0.9 (0.4–1.7)0.9 (0.4–2.0)
Brain0.04 (0.02)0.06 (0.01)0.540.7 (0.3–2.1)0.8 (0.3–2.1)0.7 (0.2–2.8)
NeuroblastomaRareRare
Other1.50 (0.14)0.73 (0.03)<0.00012.1 (1.7–2.5)1.3 (1.1–1.6)1.2 (1.0–1.5)

*Model 1: unadjusted.

†Model 2: adjusted for age (years, continuous) only.

‡Model 3: adjusted for age (years, continuous), race/ethnicity (non–Hispanic white, non–Hispanic black, Hispanic, other), health insurance coverage (any vs. none), smoking status (current smoker, former smoker, never smoked), heavy drinking (yes, consuming more than two drinks per day among men and more than one drink per day among women vs. no), BMI (kg/m2, continuous), and physical inactivity (yes vs. no).

§Rare: prevalence estimate is between 0 and 0.01%. Statistical tests are not provided due to insufficient data.

CONCLUSIONS

Our prevalence ratio estimates for the cancer of all sites among men and women were comparable to relative risk estimates in studies on cancer incidence (3,9). Our results support an association between diabetes and cancer. Previous findings have shown that diabetes is linked to an increased risk of cancers of the pancreas, liver, kidney, colorectal, urinary bladder, endometrium, breast, and non–Hodgkin’s lymphoma (3). The possible biologic mechanisms that link diabetes and cancer include hyperinsulinemia, hyperglycemia, and/or chronic inflammation (2).

These findings have significant public health implications because the strong associations of diabetes with certain cancer types may inform public health decisions and policies regarding the priorities of cancer screening and clinical management. Regular screening is an important tool to detect certain types of cancer early in their onset, particularly those with high prevalence among adults with diabetes. As shown in a previous study (10), U.S. women with diagnosed diabetes had low rates of screening for cancers of the breast, cervix, colon and rectum compared with recommended levels. Moreover, diabetic women were less likely to be screened for cervical cancer compared with nondiabetic women. Therefore, enhanced efforts may be needed to promote cancer screening, particularly for the cancers highly related to diabetes, as evidenced in our study.

Our results were subject to several limitations. First, although there is a substantial agreement in determinations of diabetes status by self-reports and those based on actual diagnoses (11), misclassification bias of the diabetes status of participants with undiagnosed diabetes could have resulted in the underestimation of our results. Second, the BRFSS survey excludes adults who have been institutionalized or hospitalized and those with only mobile telephones, which may have led us to underestimate the true prevalence of cancer.

In conclusion, our results suggest that adults with diabetes had a higher prevalence of cancer than those without diabetes. These findings highlight a need for increased attention to and efforts in preventing and screening for certain cancers to reduce the disease burden and improve the quality of life among adults with diabetes in the general population.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the Centers for Disease Control and Prevention.

Acknowledgments

No potential conflicts of interest relevant to this article were reported.

C.L. provided the study concept and design, acquired data, analyzed and interpreted data, provided statistical analysis, wrote the manuscript, and reviewed and edited the manuscript. L.S.B. and E.S.F. provided the study concept and design, interpreted data, reviewed and edited the manuscript, and supervised the study. C.A.O., J.T., and G.Z. provided the study concept and design, interpreted data, and reviewed and edited the manuscript.

ReferencesCenters for Disease Control and Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011GiovannucciEHarlanDMArcherMC Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:20722120554718VigneriPFrascaFSciaccaLPandiniGVigneriR Diabetes and cancer. Endocr Relat Cancer 2009;16:1103112319620249BaroneBBYehHCSnyderCF Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754276419088353Centers for Disease Control and Prevention. Behavioral risk factor surveillance system technical information and 2009 survey data. [Internet] 2010. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available from http://www.cdc.gov/brfss/technical_infodata/surveydata/2009.htm Accessed 1 August 2010MokdadAHStroupDFGilesWH; Behavioral Risk Factor Surveillance Team Public health surveillance for behavioral risk factors in a changing environment. Recommendations from the Behavioral Risk Factor Surveillance Team. MMWR Recomm Rep 2003;52:11212817947NelsonDEPowell-GrinerETownMKovarMG A comparison of national estimates from the National Health Interview Survey and the Behavioral Risk Factor Surveillance System. Am J Public Health 2003;93:1335134112893624BarrosAJHirakataVN Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003;3:2114567763SimonDBalkauB Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab 2010;36:18219120554237ZhaoGFordESAhluwaliaIBLiCMokdadAH Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J Gen Intern Med 2009;24:27027519089511BowlinSJMorrillBDNafzigerANJenkinsPLLewisCPearsonTA Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey. J Clin Epidemiol 1993;46:5615718501483